Rui Kang Pharmaceutical Group Investments Limited provided Group earnings guidance for six months ended 30 June 2016. For the period, the Group is expected to record a loss for its continuing operations (as opposed to a profit for the corresponding period in 2015 of approximately HKD 0.7 million). Such loss was mainly due to (i) the Group recorded a significant net loss of approximately HKD 13.3 million on financial assets at fair value through profit or loss (as opposed to a net gain of approximately HKD 18.2 million for the corresponding period in 2015); and (ii) the impairment loss on trade receivables of approximately HKD 5.0 million was recognised during the 2016 Interim Period (as opposed to nil for the corresponding period in 2015) as certain trade debts had been long overdue and the possibility of recovery was considered as remote.